论文部分内容阅读
目的:观察高敏C反应蛋白(hs-CRP)和氨基末端脑钠尿肽原(NT-proBNP)在急性冠脉综合征(ACS)行急诊冠状动脉介入治疗(PCI)术前后的临床意义及其近期预后的预测价值。方法:选择从2009年2月～2011年4月入住两家医院的ACS患者101例,均已成功行急诊PCI术,术后24 h、72 h～7 d、3～6个月测定血清hs-CRP和NT-proBNP水平;并观察随访3～6个月的主要心脏不良事件(MACE)。同时观察ACS药物治疗组52例,健康对照组40例,并进行对比分析。结果:药物治疗组的近期血清NT-proBNP水平显著高于PCI组;而药物治疗组的72 h～7d的血清hs-CRP水平显著高于PCI组;近期PCI组的MACE事件低于药物治疗组。结论:急诊PCI组3～6个月内治疗效果优于药物治疗组。血清NT-proBNP能够对ACS患者进行危险分层,预测MACE的发生率;hs-CRP可作为行急诊PCI的ACS患者的近期预后的预测因子。
Objective: To observe the clinical significance of high sensitivity C-reactive protein (hs-CRP) and NT-proBNP in patients undergoing emergency coronary intervention (PCI) with acute coronary syndrome (ACS) The prognostic value of its prognosis. Methods: A total of 101 ACS patients admitted to two hospitals from February 2009 to April 2011 were enrolled in this study. All patients underwent emergency PCI, and serum hs levels were measured at 24 h, 72 h to 7 d and 3 to 6 months after operation -CRP and NT-proBNP levels; and observed major adverse cardiac events (MACE) at 3 to 6 months of follow-up. At the same time, 52 cases of ACS drug treatment group and 40 cases of healthy control group were observed and compared. Results: Serum NT-proBNP levels in the drug-treated group were significantly higher than those in the PCI group. Serum hs-CRP level was significantly higher in the drug-treated group from 72 h to 7 d than in the PCI group. Recent MACE events were lower in the PCI group than in the drug-treated group . Conclusion: The effect of treatment in the emergency PCI group is better than that of the drug treatment group within 3 to 6 months. Serum NT-proBNP can stratify risk stratification in patients with ACS to predict the incidence of MACE; hs-CRP can be used as a predictor of recent prognosis in patients with acute PCI.